ArticleScientific reports2025
Widely targeted metabolomics study of flower buds of Styphnolobium japonicum from different producing areas.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The flower buds of Styphnolobium japonicum (FBSJ), a medicinal and food plant, exhibit broad application prospects and diverse therapeutic effects, including cooling the blood, stopping bleeding, lowering blood sugar, and exerting antioxidant and anti-inflammatory activities. To provide a reference for the identification, resource development, and utilization, a widely targeted metabolomics study was conducted on FBSJ samples from four production regions in China: Shandong (SJsd), Anhui (SJah), Hebei (SJhb), and Henan (SJhn). In this research, the metabolomic analysis provided the possibility of identifying metabolites to differentiate plants from different origin to broaden a limited metabolome coverage and unclear origin-metabolite-efficacy correlations. A UPLC-MS/MS-based metabolomics analysis was selected to investigate the metabolites of FBSJ from different geographic origins, utilizing the MWDB database and the multi-reaction monitoring mode of triple-quadrupole mass spectrometry (TQMS). A total of 1,559 metabolites were identified, of which 294 were annotated as key active ingredients in traditional Chinese medicine (TCM), and 193 as active pharmaceutical components against 11 diseases, including cancer and diabetes. Among the 708 differential metabolites identified across the four different origin groups, 176 were annotated by KEGG and distributed across 87 metabolic pathways. The most significantly altered metabolic pathway was isoflavonoid biosynthesis (p < 0.01), where SJsd samples exhibited an upregulation trend in key differential metabolites compared to the other groups. Among the 193 disease-active metabolites, 13 (e.g., 3'-Methoxydaidzein, Maackiain) were at least twofold more abundant in SJsd compared to any other origin, highlighting their critical role in explaining SJsd's superior pharmacological potential. This study provides a comprehensive molecular-level analysis of FBSJ metabolites, offering useful insights into its pharmacological analysis across different origins. These findings enhance our understanding of FBSJ metabolites annotated as anti-disease-related components in public databases and offer a valuable reference for investigating their potential in human health applications and the development of novel functional foods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.